In addition to relieving acute headaches, the drug rimegepant, which won the Hungarian Society of Experimental and Clinical Pharmacology’s “Drug of the Year” award in 2023, is also suitable for preventing further migraine attacks due to its novel mechanism of action. The award was received from Dr. Péter Ferdinandy, President of the Society, by Krisztina Zsigmond, Managing Director of Pfizer Pharmaceuticals, at a ceremony held at the Semmelweis Salon of Semmelweis University. The HUPHAR has been awarding the “Drug of the Year” prize every year since 1996 in order to support the dissemination of advanced medicines that represent breakthroughs in the treatment of a disease in Hungary, said Prof. Dr. Péter Ferdinandy, President of the company, at the award ceremony held at the Semmelweis Salon. According to him, the main criteria of the independent jury were the scientific novelty of the mechanism of action, the therapeutic niche of the product and the added value of the product in terms of domestic research and development.
